David Gandara/ilcn.org
Mar 17, 2025, 16:23
David Gandara: Interesting read on cancer drug development strategies – “Mobo”
David Gandara, Co-Director-Center for Experimental Therapeutics at UC Davis Comprehensive Cancer Center, shared a post on X:
“Interesting read on cancer drug development strategies. Here example is mobocertinib, known affectionately as ‘Mobo’, withdrawn from accelerated approval due to a negative Phase 3 trial. Overly ambitious?”
“Withdrawn NSCLC Drug: Was Ambitious Phase 3 Trial Design to Blame?”
Author: Neil Osterweil
More posts featuring David Gandara.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 19, 2025, 14:19
Mar 19, 2025, 13:04
Mar 19, 2025, 12:58
Mar 19, 2025, 12:56
Mar 19, 2025, 12:54
Mar 19, 2025, 12:35
Mar 19, 2025, 12:18
Mar 19, 2025, 12:12